Palatin Technologies, Inc. (PTN)
12.00
+0.20
(+1.69%)
USD |
NASDAQ |
Sep 14, 11:23
Palatin Technologies Enterprise Value : 11.09M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 11.09M |
| September 10, 2026 | 11.48M |
| September 09, 2026 | 12.03M |
| September 08, 2026 | 12.65M |
| September 04, 2026 | 12.69M |
| September 03, 2026 | 13.36M |
| September 02, 2026 | 12.94M |
| September 01, 2026 | 10.63M |
| August 31, 2026 | 7.872M |
| August 28, 2026 | 8.743M |
| August 27, 2026 | 8.761M |
| August 26, 2026 | 8.725M |
| August 25, 2026 | 8.548M |
| August 24, 2026 | 8.174M |
| August 21, 2026 | 7.340M |
| August 20, 2026 | 8.246M |
| August 19, 2026 | 8.21M |
| August 18, 2026 | 8.796M |
| August 17, 2026 | 7.802M |
| August 14, 2026 | 6.754M |
| August 13, 2026 | 7.890M |
| August 12, 2026 | 6.949M |
| August 11, 2026 | 3.290M |
| August 10, 2026 | 3.201M |
| August 07, 2026 | 3.929M |
| Date | Value |
|---|---|
| August 06, 2026 | 4.107M |
| August 05, 2026 | 4.231M |
| August 04, 2026 | 4.356M |
| August 03, 2026 | 4.746M |
| July 31, 2026 | 3.805M |
| July 30, 2026 | 4.000M |
| July 29, 2026 | 4.480M |
| July 28, 2026 | 3.769M |
| July 27, 2026 | 4.000M |
| July 24, 2026 | 3.814M |
| July 23, 2026 | 4.399M |
| July 22, 2026 | 4.604M |
| July 21, 2026 | 5.439M |
| July 20, 2026 | 5.190M |
| July 17, 2026 | 6.274M |
| July 16, 2026 | 5.181M |
| July 15, 2026 | 5.936M |
| July 14, 2026 | 5.848M |
| July 13, 2026 | 7.038M |
| July 10, 2026 | 7.890M |
| July 09, 2026 | 8.761M |
| July 08, 2026 | 8.370M |
| July 07, 2026 | 9.649M |
| July 06, 2026 | 9.684M |
| July 02, 2026 | 10.71M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Decoy Therapeutics, Inc. | -6.869M |
| ACADIA Pharmaceuticals, Inc. | 3.908B |
| Alnylam Pharmaceuticals, Inc. | 32.94B |
| Anika Therapeutics, Inc. | 266.01M |
| Savara, Inc. | 945.99M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.433M |
| Revenue (Quarterly) | 3.921M |
| Total Expenses (Quarterly) | 5.354M |
| EPS Diluted (Quarterly) | -0.3663 |
| Gross Profit Margin (Quarterly) | 99.57% |
| Profit Margin (Quarterly) | -36.55% |
| Earnings Yield | -11.39% |
| Normalized Earnings Yield | -11.39 |